Market Access & Communications

Communicating Value to Providers and Payers

View Now
How biotechs can strengthen their value story with advanced analytics

Read five ways biotech companies can enhance their value story with advanced analytics.

View Now
3 ways to incorporate DE&I in your communications strategy

In this infographic, we outline three ways to incorporate Diversity, Equity and Inclusion into your strategy to deliver inclusive communications that connect with a diverse and multicultural audience

View Now
Medical Communications Overview Brochure

Engaging those that matter most

View Now
Lessons from China and the United States on the use of RWE in regulatory submissions

View Now
Loading, please wait

Error - something went wrong!

Speak to one of our experts today

We'll be in touch shortly!
Loading, please wait

Error - something went wrong!

Register now for full access to all the content

Thank you for registering!
Four reasons to conduct robust natural history studies before clinical trials

Lucas Kempf, former regulator, reflects on his time at the FDA and outlines why companies should invest in a high-quality natural history study.

Learn More
Can Synthetic / External Control Arms meet regulatory and HTA requirements?

This article summarizes a recent panel discussion where experts from Parexel and biotech company, MorphoSys, shared their experiences from recent pioneering efforts in RWE.

View Now
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

In this blog, our experts explore how to develop multi-purpose, patient-centric lay language summaries with the patient audience firmly in mind.

Learn More
Strategies for External Control Arms

View Now
Tips for building your oncology reimbursement strategy

In this infographic, we share five tips for building an effective reimbursement strategy for your oncology product.

Learn More
101 guide for real-world evidence

We have created this guide to simplify the terminology of real-world evidence (RWE) and outline some of the strategic options available.

Learn More
Payer insights for cell and gene therapies

Emma Medin, VP, Pricing & Market Access, shares three payer insights to help you price appropriately for your cell or gene therapy.

Watch Video
Maximizing your virtual investigator meeting results

Learn how Parexel brings the principles and energy from face-to-face investigator meetings to an interactive and engaging virtual environment.

Watch Video
Evolution of Medical Communication Engagement

Parexel colleagues celebrate #MedComms Day as they talk through how the medical communications landscape was turned upside down for onsite meetings and scientific congresses in 2020 and what this mean

Watch Video
Impact of Real-World Evidence on Payers & Patients

Dr. Scott Gottlieb, Former Commissioner of the Food and Drug Administration speaks with Parexel’s Peyton Howell, Executive Vice President, Chief Commercial & Strategy Officer and Sy Pretorius, Executi

Watch Video
Real-World Evidence: The Feedback Loop

RWE experts Leanne Larson, Senior Vice President and Worldwide Head, Real-World Evidence and Access and Amy McKee, Vice President, Regulatory and Access dig deeper into the evolving role of RWE.

Watch Video
Importance of Diversity, Equity and Inclusion (DE&I) in medical communications

Parexel communications experts celebrate #MedComms day by discussing how new guidelines and changes in the clinical trial space translate to medical communications and how Parexel plans to approach fu

Watch Video
Navigating the new normal for meetings – now and for the future

View Now
Virtual meetings are easy, right?

Recommendations for navigating the "new normal" and how to prepare for the future.

Learn More
EMA Guidance: Management of Clinical Trials - What it means for Patients?

A lay summary for patients participating in clinical trials

View Now
Loading More...

Regulatory & Access Resources

Market Access & Communications